UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 10900 Wilshire Blvd. Suite 600 Los Angeles, California 9002 ...

Financial Performance - ChromaDex's total revenues for the fiscal year ended December 31, 2019, were approximately $46.3 million, up from $31.6 million in 2018, representing a growth of 46.5%[30] - Net sales of TRU NIAGEN® increased by $17.6 million, from $18.5 million in 2018 to $36.1 million in 2019, offsetting a 28% decrease in the ingredients segment net sales[26] - ChromaDex's ingredients segment net sales decreased from $8.6 million in 2018 to $6.2 million in 2019, reflecting a strategic reduction in NIAGEN® resellers[26] - The company incurred net losses of approximately $32.1 million and $33.3 million for the years ended December 31, 2019, and December 31, 2018, respectively, with an accumulated deficit of approximately $121.9 million as of December 31, 2019[93] - Cash and cash equivalents totaled approximately $18.8 million as of December 31, 2019, with expectations that current cash and operations will suffice for projected plans through at least the next twelve months[94] - Working capital at the end of years 2019 and 2018 was approximately $4.1 million and $3.1 million, respectively[82] Market Expansion and Strategy - The global dietary supplements market size was estimated at $123 billion in 2019 and is expected to grow at a CAGR of 8.2% to about $232 billion by 2027, indicating a favorable market environment for ChromaDex[36] - ChromaDex received a positive opinion from the European Food Safety Authority on nicotinamide riboside (NR) as a novel food ingredient in 2019, facilitating international market expansion[27] - The company plans to expand its TRU NIAGEN® products into new international markets, focusing on obtaining additional regulatory approvals[38] - The company has successfully launched TRU NIAGEN® in Hong Kong, Macau, Singapore, New Zealand, and Canada, and is currently selling in China, the UK, Canada, and Japan[50] Research and Development - The company has approximately 190 partnerships with leading universities and research institutions globally, enhancing its research capabilities in the NAD space[22] - The company is conducting additional clinical trials to validate the health benefits associated with NIAGEN® and TRU NIAGEN®[42] - Research and development costs for the fiscal years ended December 31, 2019, and December 31, 2018, were approximately $4.4 million and $5.5 million, respectively[79] - The company completed a second human clinical trial on its proprietary ingredient NIAGEN®, demonstrating that NAD+ levels rose in response to the dose of NIAGEN®[78] Sales and Marketing - The company employs various sales and marketing strategies for TRU NIAGEN®, including social media, internet advertising, and partnerships with influencers[45] - Major customers accounted for more than 10% of total sales, with A.S. Watson Group contributing 15.8% in 2019[62] Competition and Market Risks - The company faces competition from Elysium Health in the consumer products segment and various ingredient suppliers in the ingredients segment[64] - The company faces significant competition, with many competitors having greater financial and operational resources, which could lead to the development of superior technologies that may harm the company's market position[132] - The markets for the company's products are highly price competitive, and failure to respond to price competition could lead to reduced sales revenues and increased losses[133] Intellectual Property and Regulatory Risks - The company protects its intellectual property through patents, trademarks, and copyrights, aiming for long-term royalty payments from proprietary ingredients[68] - The ability to protect intellectual property rights is uncertain, and failure to do so could have a material adverse effect on the company's business[145] - Regulatory approval may be required in the future for the company's goods, which could delay revenue generation until such approval is obtained[190] - The company cannot ensure that any developed goods will meet all regulatory requirements necessary for marketing clearance, which could hinder commercialization efforts[192] Financial and Operational Challenges - The company may seek to raise additional capital within the next twelve months to meet projected operating plans and fund long-term strategic objectives, which could lead to dilution for existing stockholders[97] - The company has no commitments for additional financing and may not be able to obtain it on favorable terms, which could adversely affect future performance[94] - The company may face significant costs and reputational damage from product liability claims, which could adversely affect its business and financial condition[119] - The company bears financial risk if contracts are under-priced or if cost estimates are exceeded, which could adversely affect business operations and cash flows[164] Future Outlook - Future revenue is expected to significantly depend on the market acceptance of the TRU NIAGEN® product, which is critical for the company's continued success[105] - The company anticipates that operating expenses will continue to increase due to the expansion of product launches and hiring of additional personnel[107] - The company's future revenue and operating results are difficult to forecast due to various uncontrollable factors, including competition and economic conditions[131] Legal and Compliance Issues - The company is currently engaged in litigation with Elysium Health, which represented 19% of net sales for the year ended December 31, 2016, and has not made purchases since August 9, 2016[99] - The company has written off approximately $2.7 million as uncollectible expense due to Elysium's failure to pay for previous purchase orders[100] - The company may become involved in securities class action litigation due to extreme fluctuations in stock price, diverting management's attention[208]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 10900 Wilshire Blvd. Suite 600 Los Angeles, California ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 26-2940963 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 10900 Wilshire Blvd. Suite 650, Los Angeles, California (Add ...

Financial Performance - For the three months ended March 31, 2019, total net sales increased by 53% to $10.048 million compared to $6.567 million for the same period in 2018 [101]. - The company reported a net loss of $8.337 million for the three months ended March 31, 2019, compared to a net loss of $8.443 million for the same period in 2018 [101]. - Gross profit for the consumer products segment was $4.383 million, representing a 128% increase from $1.923 million in the prior year [112]. - The cost of sales as a percentage of net sales decreased by 5% to 47% for the three-month period ended March 31, 2019, compared to 52% for the same period in 2018 [107]. - The company has incurred aggregate losses of approximately $98.1 million since inception through March 31, 2019 [131]. Sales and Segment Performance - Consumer products segment sales rose by 146% to $7.454 million, while ingredient sales decreased by 37% to $1.494 million [103]. - The decrease in sales for the ingredients segment is attributed to the company's strategic shift towards expanding its consumer products business [104]. - The company expects sales for the consumer products segment to continue to grow over the next twelve months [103]. Cash and Liquidity - As of March 31, 2019, the company had approximately $19.3 million in cash and cash equivalents, sufficient to meet projected operating plans for at least the next twelve months [97]. - Net cash used in operating activities decreased to approximately $3.0 million in Q1 2019 from approximately $4.0 million in Q1 2018 [134]. - Net cash used in investing activities was approximately $0.3 million for Q1 2019, compared to $0.2 million in Q1 2018 [137]. - Net cash provided by financing activities was approximately $0.1 million in Q1 2019, compared to $0.2 million used in Q1 2018 [138]. Expenses and Investments - Sales and marketing expenses for consumer products increased by 44% to $3,917,000 for the three months ending March 31, 2019, compared to $2,727,000 in the same period in 2018 [117]. - Total research and development expenses decreased by 19% to $1,168,000 for the three months ending March 31, 2019, down from $1,439,000 in the same period in 2018 [120]. - General and administrative expenses rose by 22% to $8,331,000 for the three months ending March 31, 2019, compared to $6,828,000 in the same period in 2018 [122]. - Share-based compensation increased to approximately $1.8 million in Q1 2019 from approximately $1.1 million in Q1 2018 [122]. Research and Development - The company has approximately 170 partnerships with leading universities and research institutions globally, enhancing its research capabilities in the NAD space [94]. - The company plans to continue increasing marketing, research, and development efforts for its flagship ingredient, NIAGEN® nicotinamide riboside, and its consumer branded product TRU NIAGEN® [101]. Other Financial Metrics - Interest income improved to $35,000 in Q1 2019 from a net expense of $44,000 in Q1 2018 [125]. - The effective tax rate remained approximately 0% for both Q1 2019 and Q1 2018 due to a full valuation allowance against the deferred income tax balance [126].

Financial Performance - ChromaDex's total revenues for the fiscal year ended December 31, 2018, were approximately $31.6 million, up from $21.2 million in 2017, representing a growth of 49%[33] - Net sales of TRU NIAGEN® increased by $13.0 million, from $5.5 million in 2017 to $18.5 million in 2018, offsetting a 23% decline in the ingredients segment[27] - The ingredients segment net sales decreased from $11.1 million in 2017 to $8.6 million in 2018, a decline of 23%[27] - The company incurred net losses of approximately $33.3 million and $11.4 million for the years ended December 31, 2018, and December 30, 2017, respectively, with an accumulated deficit of approximately $90 million as of December 31, 2018[99] - Cash and cash equivalents totaled approximately $22.6 million as of December 31, 2018, with expectations that current cash and operations will suffice for projected plans over the next twelve months[100] - As of December 31, 2018, the company's working capital was approximately $3.1 million, down from $7.4 million in 2017, indicating a need for increased working capital as segments grow[88] Market Trends and Opportunities - The global anti-aging market is projected to grow at a CAGR of 5.8% through 2021, reaching approximately $330 billion[28] - The worldwide market for vitamins and dietary supplements was approximately $106 billion in 2018, expected to grow at a CAGR of 3.0% to about $123 billion by 2023[38] - ChromaDex plans to continue expanding its TRU NIAGEN® brand internationally, having launched in Hong Kong, Macau, Singapore, New Zealand, and Canada[29] - The company aims to enhance its proprietary ecommerce platforms and expand its marketing and distribution in new international markets[41] Research and Development - Research and development costs for the fiscal years ended December 31, 2018, and December 30, 2017, were approximately $5.5 million and $4.0 million, respectively[85] - The company completed a second human clinical trial on NIAGEN® in 2018, showing that NAD levels rose in response to doses, with elevated levels sustained throughout the eight-week treatment period[84] - The company plans to explore cost-saving processes for existing products through its research and development laboratory in Longmont, Colorado[85] Regulatory and Compliance - The company is subject to various U.S. federal regulations, including those from the FDA and FTC, which govern production activities and advertising claims[58][63] - The company is focusing on obtaining additional regulatory approvals to expand TRU NIAGEN® marketing and distribution in new international markets[55] - The company protects its intellectual property through patents, trademarks, and licenses, anticipating long-term royalty payments from proprietary ingredients[74] - The company is evaluating strategic joint ventures to rapidly expand distribution in Asia[55] Competition and Market Risks - The company faces direct competition from Elysium Health in the consumer products segment, while its ingredients segment has little direct competition due to exclusive intellectual property[69][70] - Global economic conditions may adversely affect sales, particularly for discretionary nutritional products, impacting financial results[114] - The company faces significant competitive risks due to price competition, which could lead to reduced sales revenues and increased losses if competitors lower their prices[143] - Adverse changes in consumer perception regarding nutritional supplements could materially affect demand for the company's products[126] Customer Dependency and Sales - Major customers included A.S. Watson Group, accounting for 19.4% of total sales in 2017, and Thorne Research at 10.2%[68] - One customer accounted for approximately 10% of the company's sales for the year ended December 31, 2018, indicating a significant dependency on key customers[108] - NIAGEN® sales accounted for approximately 60% of the ingredient segment's total sales in 2018, equating to 16% of overall revenue, highlighting the importance of this product[112] - The company has minimal backlog orders for its consumer products and ingredients segments, with a small backlog of approximately $25,000 for analytical reference standards[91] Legal and Litigation - The company is engaged in litigation with Elysium, which represented 19% of net sales for the year ended December 31, 2016, and has not made purchases since August 2016[105] - The company is involved in ongoing litigation with Elysium Health, which includes claims of breach of supply agreements and misappropriation of trade secrets[214] - The Patent Trial and Appeal Board upheld a claim of the '086 Patent, preventing Elysium from raising invalidity arguments in ongoing litigation[216] - The company is currently in discovery regarding allegations made by Elysium Health[215] Operational Challenges - The company relies on key personnel, and the loss of any could negatively impact business operations[137] - The company relies on a limited number of third-party suppliers for raw materials, which poses risks related to pricing, availability, and quality[173] - The company may need to contract with third parties for marketing and distribution, which could lower product revenue and increase costs[178] - Cyber security threats pose risks to the company's operations, potentially leading to disrupted operations and increased costs[180] Future Outlook and Strategic Plans - The company intends to consider acquisitions of similar or complementary businesses or products, but there is no assurance of success in identifying attractive candidates or completing acquisitions on favorable terms[175] - The company expects operating expenses to continue increasing due to the expansion of product launches and hiring additional personnel[117] - The success of the consumer product business is linked to the effectiveness of marketing efforts, which will significantly influence future growth and profitability[123] - The company has made forward-looking statements regarding future operating results, which may not be met, potentially affecting stock price[205]